Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novo Nordisk (NVO) and Kezar Life Sciences (KZR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVOResearch Report) and Kezar Life Sciences (KZRResearch Report).

Novo Nordisk (NVO)

Novo Nordisk received a Sell rating from UBS analyst Michael Leuchten today. The company’s shares closed last Monday at $112.89.

Leuchten has an average return of 11.2% when recommending Novo Nordisk.

According to TipRanks.com, Leuchten is ranked #1719 out of 7915 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novo Nordisk with a $131.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Kezar Life Sciences (KZR)

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Kezar Life Sciences, with a price target of $17.00. The company’s shares closed last Monday at $5.78, close to its 52-week low of $4.31.

According to TipRanks.com, Archila is a 1-star analyst with an average return of -0.7% and a 37.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Prometheus Biosciences, and Horizon Therapeutics.

Currently, the analyst consensus on Kezar Life Sciences is a Strong Buy with an average price target of $19.67, a 232.3% upside from current levels. In a report released today, Jefferies also maintained a Buy rating on the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed